<DOC>
	<DOCNO>NCT00715676</DOCNO>
	<brief_summary>This study evaluate effect 1-year administration vitamin D analog 2-methylene-19-nor- ( 20S ) -1alpha , 25-dihydroxyvitamin D3 ( DP001 ) bone mineral density ( BMD ) , safety , tolerability .</brief_summary>
	<brief_title>Phase 2 Safety Efficacy Study Vitamin D Compound ( DP001 ) Postmenopausal Women With Low Bone Mineral Density</brief_title>
	<detailed_description>DP001 vitamin D analog show stimulate bone formation pre-clinical study . In Phase 1B study postmenopausal woman , increase bone formation marker , osteocalcin , evident without increase serum calcium . The aim study determine 1-year administration DP001 postmenopausal woman osteopenia result significant increase BMD dose safe well tolerate .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Dihydroxycholecalciferols</mesh_term>
	<mesh_term>Vitamin A</mesh_term>
	<mesh_term>Bone Density Conservation Agents</mesh_term>
	<mesh_term>Retinol palmitate</mesh_term>
	<criteria>Postmenopausal female subject , define amenorrheic least 5 year Body Mass Index 18 35 Osteopenic Generally healthy Informed consent Exclusion Criteria History evidence acute unstable chronic hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , psychiatric , neurologic disease Current recent treatment medication product affect vitamin D metabolism , calcium balance , bone turnover , investigational drug therapy 12lead electrocardiogram demonstrating QTc ( QT interval correct heart rate ) &gt; 450 millisecond screen Abnormal creatinine clearance Elevated urinary calcium level Vitamin D deficiency Excessive dietary calcium vitamin D intake Current use illicit drug and/or history alcohol abuse</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>2-methylene-19-nor- ( 20S ) -1a , 25-dihydroxyvitamin D3</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Bone Density Conservation Agents</keyword>
	<keyword>Bone Regeneration</keyword>
</DOC>